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Background. Several psychometric instruments are available for the diagnostic interview of subjects at ultra high risk (UHR) of
psychosis.Their diagnostic comparability is unknown.Methods. All referrals to the OASIS (London) or CAMEO (Cambridgeshire)
UHR services fromMay 13 to Dec 14 were interviewed for a UHR state using both the CAARMS 12/2006 and the SIPS 5.0. Percent
overall agreement, kappa, the McNemar-Bowker 𝜒2 test, equipercentile methods, and residual analyses were used to investigate
diagnostic outcomes and symptoms severity or frequency. A conversion algorithm (CONVERT) was validated in an independent
UHR sample from the Seoul Youth Clinic (Seoul). Results. There was overall substantial CAARMS-versus-SIPS agreement in the
identification of UHR subjects (𝑛 = 212, percent overall agreement = 86%; kappa = 0.781, 95% CI from 0.684 to 0.878; McNemar-
Bowker test = 0.069), with the exception of the brief limited intermittent psychotic symptoms (BLIPS) subgroup. Equipercentile-
linking table linked symptoms severity and frequency across the CAARMS and SIPS. The conversion algorithm was validated in
93 UHR subjects, showing excellent diagnostic accuracy (CAARMS to SIPS: ROC area 0.929; SIPS to CAARMS: ROC area 0.903).
Conclusions.This study provides initial comparability data betweenCAARMS and SIPS andwill informongoingmulticentre studies
and clinical guidelines for the UHR psychometric diagnostic interview.
“The comparability of measurements made in differing circumstances by different methods and investigators is a fundamental
precondition for all of science”
Dorans and Holland (2000)
1. Introduction
The development of psychometric tools to prospectively
identify subjects at ultra high clinical risk (UHR hereafter)
of psychosis has allowed preventative screening [1], diagnosis
[2], and interventions [3] to be feasible in psychiatry. In
1991, Jackson andMcGorry were the first to initiate reliability
studies to psychometrically assess first-episode subjects via a
semistructured interview in order to ascertain the presence
of prodromal symptoms [4]. On the basis of their results, in
1995 Yung and colleagues set up the first clinical service for
UHR individuals and conceived the first comprehensiveUHR
psychometric instrument [5]. The Comprehensive Assess-
ment of At-Risk Mental States (CAARMS hereafter) was
developed at the Personal Assessment and Crisis Evaluation
(PACE) Clinic in Melbourne [6] and has been widely used
in Australia, Asia, and Europe to interview for “At-Risk
Mental State, ARMS,” criteria. Their pivotal work resulted
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in the formulation of three UHR criteria: attenuated psy-
chotic symptoms (APS hereafter), brief limited intermittent
psychotic symptoms (BLIPS hereafter), and trait vulnerability
plus a marked decline in psychosocial functioning (Genetic
Risk and Deterioration syndrome: GRD hereafter). A few
years later, in 1999, based on these criteria, Miller et al. (1999)
[7] developed a similar psychometric instrument for quanti-
tatively rating symptoms in patients at UHR of psychosis [8],
in the Prevention through Risk Identification, Management
and Education (PRIME) Clinic in New Haven (USA): the
Structured Interview for Psychosis-Risk Syndrome (SIPS
hereafter) [8] (for a detailed genealogy of the CAARMS and
SIPS see [9, 10]).
The CAARMS and the SIPS address the same construct
and use similar criteria, and they can deliver comparable
positive predictive values over follow-up time [11, 12]. How-
ever, their operationalization differs [10], with substantial
changes over different versions of the instruments [10]. Oper-
ationalization differences include disparity in psychopatho-
logical definitions of the APS, time and frequency criteria,
functional decline criterion, BLIPS criteria, assessment of
comorbidities, and substance misuse (see Tables 1 and 2
and eTable 1 (in Supplementary Material available online
at http://dx.doi.org/10.1155/2016/7146341) for a detailed com-
parison of CAARMS 12/2006 and SIPS 5.0).
The resulting overall weight of similarities and differ-
ences between the two instruments on UHR identification
is unknown. Psychometric diagnostic uncertainty questions
validity of the UHR diagnostic interview, creating incon-
sistencies between clinicians or researchers and misunder-
standings in patients [13]. Comparability of current clinical,
neurobiological, cognitive, and therapeutic UHR research
findingsmay be also questionable and compromised, with the
risk of “a profusion of statistically significant, but minimally
differentiating” [14] results of limited clinical utility. Psycho-
metric uncertaintymay significantly impact the development
of future large-scale UHR multicentre studies, by amplifying
heterogeneity across individual sites. These concerns and
speculations have never been tested empirically. To resolve
the “current confusion” [13], research studies allowing “a
thorough evaluation of the comparability of samples” [13]
have been urgently advocated [10, 15].
We present here the first study addressing the psychome-
tric comparability of the CAARMS 12/2006 [16] versus SIPS
5.0 [8]. Our principal aim was to test if the CAARMS 12/2006
and the SIPS 5.0 can equally identify UHR subjects in a large
pool of individuals referred to high-risk services for potential
UHR symptoms. Our second aim was to qualitatively inves-
tigate potential discrepancies and to link the severity and fre-
quency of symptoms with equipercentile-linking tables. Our
third aim was to develop a pragmatic algorithm to convert
individual cases across the two instruments, to implement
it in an automated conversion package (CONVERT), and to
validate it in an independent UHR sample.
2. Methods
2.1. Samples. We included all referrals to the OASIS (Out-
reach And Support In South London; http://www.slam
.nhs.uk/oasis) and CAMEO (Cambridgeshire and Peter-
borough Assessing Managing and Enhancing Outcomes,
http://www.cameo.nhs.uk/) clinics assessed for a UHR state
in the period May 2013–December 2014. The OASIS team
was started in 2001 [17] and it is specialized in detecting
and treating subjects at UHR of psychosis aged 16–35 [17].
CAMEO was started in 2007 and it is an early intervention
in psychosis service which offers management for UHR
people aged 17–35 in Cambridgeshire, UK, and provides
initial assessments to those under 17. Referrals for both
services are accepted frommultiple sources including general
practitioners, othermental health services, school and college
counselors, relatives, and self-referrals [18]. The validation
sample for CONVERT included all referrals to the Seoul
Youth Clinic assessed for a UHR state with the CAARMS
12/2006 and the SIPS 5.0 as part of the standard clinical
practice. The Seoul Youth Clinic was started in 2004 and
offers assessment and treatment for UHR people aged 15–35
in Seoul, South Korea [19]. Subjects are recruited from Seoul
NationalUniversityHospital and other psychiatric clinics and
public mental health centers or they can contact the clinic by
telephone or an Internet homepage.
2.2. Procedure. The study samples were designed to reflect
at-risk populations as they are encountered in day-to-day
practice: all subjectswere drawn from the samepool of people
referred to high-risk services because of suspect prodromal
signs and symptomsof psychosis. Avoiding the use of external
and non-help-seeking control groups who do not reflect the
clinical composition of people actually assessed in high risk
is essential to properly compare the diagnostic abilities of
the two instruments. Furthermore, we only included subjects
who were directly assessed with both psychometric instru-
ments during face-to-face interviews, excluding those who
declined the full assessment or who were unable to complete
it. Responsible clinicians interviewed the participants with
the CAARMS 12/2006 [16] and with the SIPS 5.0 [8]. The
training procedure and the interrater reliability of the OASIS
and CAMEO clinicians have been fully detailed in Supple-
mentary eMethod 1. Subjects accessing the Seoul YouthClinic
are usually assessedwith bothCAARMS 12/2006 and SIPS 5.0
instruments as part of standard clinical practice, and further
details are provided in an independent publication [19].
2.3. Clinical Measures. The primary outcome measure was
the psychometric diagnosis under the CAARMS 12/2006 [16]
versus SIPS 5.0 [8] at the end of the diagnostic interview
assessment: at risk of psychosis (UHR+ hereafter), not at
risk of psychosis (UHR−hereafter), andPsychosis. Secondary
outcome measures included the severity and frequency of
UHR as measured on the diagnostic subscales: P1–P4 on
the CAARMS 12/2006 and P1–P5 on the SIPS 5.0 (eTable 1).
Additional variables recorded were subgroup of UHR+ (APS,
BLIPS, and GRD), age, gender, ethnicity, baseline comorbid
diagnosis, duration of follow-up, and functional status (GAF
in the SIPS 5.0 and SOFAS in the CAARMS 12/2006).
2.4. Statistical Analysis. The primary aim of the study
was investigated by comparing the diagnostic outcomes
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Table 1: UHR criteria: similarities and differences between the SIPS 5.0 and the CAARMS 12/2006 (see also eTable 1 for details on the
psychopathological dimensions investigated by P1–P5 and P1–P4).
(a) Rating system
SIPS version 5.0 [8] CAARMS version 12/2006 [16]
Subscales
P1: Unusual Thought Content/Delusional Ideas
P2: Suspiciousness/Persecutory Ideas
P3: Grandiose Ideas
P4: Perceptual Abnormalities/Hallucinations
P5: Disorganized Communication
P1: Unusual Thought Content
P2: Non-Bizarre Ideas
P3: Perceptual Abnormalities
P4: Disorganized Speech
Frequency
1: at least several min per d at least 1/mo
2: several min/d at least once/wk in the past mo
3: at least 1 h/d for at least 4 d/wk over 1mo
0: absent
1: less than 1/mo
2: 1/mo to 2/wk, <1 h per occasion
3: 1/mo to 2/wk, >1 h per occasion, OR 3
to 6/wk, <1 h per occasion
4: 3 to 6/wk, > 1 h per occasion, OR daily,
<1 h per occasion
5: daily, >1 h per occasion, OR several
times/d
6: continuous
Substance use Exclusion criterion if strongly intertwined withsymptoms
0: no relation to substance use noted
1: occurs in relation to substance use and
at other times as well
2: noted only in relation to substance use
Distress Subjective qualifierNot used to determine an individual’s UHR status
Rated on scale 0–100
Not used to determine an individual’s
UHR status
(b) Attenuated psychotic symptoms
Attenuated positive symptom psychosis-risk syndrome
SIPS version 5.0 [8]
Attenuated psychosis group
CAARMS version 12/2006 [16]
Inclusion
criteria
Severity score of 3–5 on at least one of P1–P5
PLUS
Frequency score of 2 on P1, P2, P3, P4, and/or P5
Subthreshold intensity
Severity score of 3–5 on P1, 3–5 on P2, 3-4 on P3,
and/or 4-5 on P4
PLUS
Frequency score of 3–6 on P1, P2, P3, and/or P4
Subthreshold frequency
Severity score of 6 on at least one of P1, P2, and P4
and/or 5-6 on P3
PLUS
Frequency score of 3 on P1, P2, P3, and/or P4
Onset
Symptoms should have begun within the past year OR
currently rate one or more scale points higher
compared to 12 months before
Symptoms that occurred over the past month only are
rated
Symptoms should have been present in the
previous 12mo AND for not longer than 5 y
Level of
functioning No social/occupational dysfunction requirement
30% drop in SOFAS score from premorbid level,
sustained for a mo, within the past 12mo OR
SOFAS score <50 for the past 12mo or more
Exclusion
criteria
Symptoms are strongly intertwined temporally with
substance use episodes (substance-induced psychosis
may be considered)
Symptoms occur only during peak intoxication
from a substance known to be associated with
psychotic experiences (e.g., hallucinogens,
amphetamines, and cocaine)
Symptoms are better accounted for by another DSM
diagnosis —
Past psychosis ruled in according to information
obtained through the initial screen and evaluated using
the POPS
The person has had a previous psychotic episode
(treated or untreated)
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(c) Brief limited intermittent psychotic symptoms
Brief intermittent psychotic symptom psychosis-risk syndrome
SIPS version 5.0 [8]
Brief limited intermittent psychotic symptoms group
CAARMS version 12/2006 [16]
Inclusion
criteria
Severity score of 6 on at least one of P1–P5
PLUS
Frequency score of 1 on P1, P2, P3, P4, and/or P5
Severity score of 6 on at least one of P1, P2, and P4
and/or 5-6 on P3
PLUS
Frequency score of 4–6 on P1, P2, P3, and/or P4
Onset Symptoms should have reached a psychotic level of intensity inthe previous 3mo
Symptoms should have been present in the previous
12mo and for not longer than 5 y
Duration Up to 3mo Up to 7 d
Level of
functioning No social/occupational dysfunction requirement
30% drop in SOFAS score from premorbid level,
sustained for a mo, within the past 12mo OR SOFAS
score <50 for the past 12mo or more
Exclusion
criteria
Symptoms are strongly intertwined temporally with substance
use episodes (substance-induced psychosis may be considered)
Symptoms occur only during peak intoxication from a
substance known to be associated with psychotic
experiences (e.g., hallucinogens, amphetamines, and
cocaine)
Symptoms are better accounted for by another DSM diagnosis —
Past psychosis ruled in according to information obtained
through the initial screen and evaluated using the POPS
The person has had a previous psychotic episode
(treated or untreated)
Symptoms are seriously disorganizing and dangerous —
— Symptoms do not resolve spontaneously (withoutantipsychotic medication)
(d) Genetic risk and deterioration syndrome
Genetic risk and deterioration psychosis-risk syndrome
SIPS version 5.0 [8]
Vulnerability group
CAARMS version 12/2006 [16]
Inclusion criteria
The patient meets criteria for Schizotypal Personality
Disorder
OR
The patient has a first-degree relative with a psychotic
disorder
Schizotypal Personality Disorder in identified patient
OR
Family history of psychosis in a first-degree relative
Level of functioning 30% drop in GAF score over the last mo as compared to12mo before
30% drop in SOFAS score from premorbid level,
sustained for a mo, within the past 12mo OR SOFAS
score <50 for the past 12mo or more
CAARMS, Comprehensive Assessment of At-Risk Mental States; d, day; GAF, Global Assessment of Functioning; h, hour; min, minute; mo, month; SIPS,
Structured Interview for Psychosis-Risk Syndrome; SOFAS, Social and Occupational Functioning Assessment Scale; UHR, ultra high risk; wk, week.
Table 2: Psychosis threshold: similarities and differences between the SIPS 5.0 and the CAARMS 12/2006.
Presence of psychotic syndrome
SIPS version 5.0
Psychosis threshold
CAARMS version 12/2006
Inclusion criteria
Severity score of 6 on at least one of P1–P5
PLUS
Frequency score of 3 on P1, P2, P3, P4, and/or P5
Severity score of 6 on at least one of P1, P2, and P4
and/or 5-6 on P3
PLUS
Frequency score of 4–6 on P1, P2, P3, and/or P4
Urgency Symptoms are seriously disorganizing and dangerous(a) —
CAARMS, Comprehensive Assessment of At-Risk Mental States; SIPS, Structured Interview for Psychosis-Risk Syndrome.
(a) “‘Dangerous’ is taken tomeanphysically dangerous, for example, risk of death or serious physical injury, and ‘disorganizing’means potentially psychosocially
dangerous, for example, risk of seriously damaging work relations, social relations, family relations, or personal dignity.” Personal communication from the
authors of the SIPS, published with permission (see Acknowledgments).
(i.e., UHR+, UHR−, and Psychosis) under CAARMS 12/2006
versus SIPS 5.0 in OASIS and CAMEO samples, using IBM
SPSS Statistics 22 and STATA 13 software. Specifically, we
calculated percent overall agreement, kappa (with its 95%CI),
and the exact McNemar-Bowker 𝜒2 test to assess marginal
errors. Given evidence that baseline functional status is
a strong predictor of longitudinal outcome [20], we further
performed a weighted kappa analysis, weighting the three
groups according to their relative baseline functional level,
as established in our previous meta-analysis (i.e., UHR− = 1,
UHR+ = 0.84, and Psychosis = 0, eFigure 1, adapted from
[20]). We additionally estimated the prevalence and bias
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adjusted kappa (PABAK) [21] which adjusts the kappa for
imbalances caused by differences in prevalence and bias
[22]. Interpretation of the kappa values varies, but some
guidelines were provided by Landis and Koch (1977) for
kappa coefficients suggesting that kappa of 0.01 indicates
“poor” agreement; kappa values from 0.01 to 0.20 indicate
“slight” agreement; kappa values from 0.21 to 0.40 indicate
“fair” agreement; kappa values from 0.41 to 0.60 indicate
“moderate” agreement; kappa values from 0.61 to 0.80 indi-
cate “substantial” agreement; kappa values from 0.81 to 1.00
indicate “almost prefect” agreement [23].
The secondary aim of the study was investigated using
post hoc explorative residual analyses comparing different
subgroups (i.e., UHR−, GRD, APS, BLIPS, and Psychosis),
Bonferroni-corrected for multiple comparisons. Qualitative
analyses of discrepancies across the two instruments were
also conducted, to better elucidate the impact of each specific
cell on the overall results. We further converted the severity
and frequency of symptoms by employing a linking method,
using equate 2.0-3 [24] under R 3.1.2 software.This method is
detailed in eMethod 2.
The third aim of the study was investigated with qualita-
tive a priori comparisons of a priori operationalization differ-
ences between theCAARMS 12/2006 and SIPS 5.0, as detailed
in Tables 1 and 2. Equipercentile linking, percent overall
agreement, and kappa estimated above here in theOASIS and
CAMEO services were not used for the development of this
pragmatic algorithm. A software engineer (JL) then imple-
mented the conversion algorithm in an automated package.
CONVERT is a Python application which implements the
conversions of individual outcomes (UHR−, UHR+ [GRD,
APS, and BLIPS], and Psychosis) between the CAARMS
12/2006 and SIPS 5.0 as proposed by the conversion algo-
rithm. CONVERT takes as input a ∗.xls file and produces
as output a ∗.xls file. To freely download the tool and the
template ∗.xls input file and get further details please visit
https://bitbucket.org/ioppn/convert. We first piloted CON-
VERT in the OASIS and CAMEO dataset and then validated
it in an independentUHR sample recruited at the Seoul Youth
Clinic. Diagnostic accuracy measures of CONVERT were
analysed with respect to both CAARMS 12/2006-to-SIPS 5.0
and SIPS 5.0-to-CAARMS 12/2006 conversions and included
percent overall agreement, kappa (with its 95% CI), PABAK,
sensitivity, specificity, and nonparametric ReceiverOperating
Characteristic (ROC) analyses.
3. Results
3.1. Samples and Raters Characteristics. The OASIS and
CAMEO sample consisted of 212 consecutive help-seeking
subjects recruited between May 2013 and December 2014
(OASIS = 128, CAMEO = 84). Of the 212 subjects, 82 were
females (38.7%). The mean age was of 24.13 years (SD =
4.98, range = 16–35 years). The majority of subjects were
white British (50%), followed by black British (26.1%) and
subjects from Asia (4.1%), Africa (4.3%), and South America
(1.1%) and from other European countries (11.4%). The mean
SOFAS score was of 51.51 (SD = 17.26, median = 48, and
range = 18–95). Sociodemographic characteristics of referrals
across OASIS andCAMEOare detailed in the Supplementary
Material (eTable 2). Each rater interviewed on average 35.33
(SD 31.1) subjects. The IRR for the principal diagnostic
outcome (𝑛 = 21) was of kappa = 0.902 for the CAARMS
12/2006 and kappa = 0.854 for the SIPS 5.0.The IRRs for each
subscale were in the excellent range: CAARMS 12/2006 kappa
from 0.863 to 0.915 and SIPS 5.0 kappa from 0.815 to 0.923
(eMethod 1).
The validation sample from the Seoul Youth Clinic
included 93 UHR subjects, with a mean age of 20.24 years
(SD = 4.00, range = 15–33), mostly males (29% females), of
Asian ethnicity [19].
3.2. Diagnostic Comparison of CAARMS 12/2006 and SIPS
5.0 in OASIS and CAMEO. The percent overall agreement
was 86.32% (expected agreement by chance 37.42%) and the
kappa was substantial 0.781 (𝑍 = 15.83, 𝑝 < 0.001, and 95%
CI from0.684 to 0.878) with theMcNemar-Bowker𝜒2 (7.087)
resulting in 𝑝 = 0.069. The prevalence and bias adjusted
kappa was 0.795 (95% CI from 0.731 to 0.856). The kappa
remained substantial when it was estimated in the subset
of subjects rated by independent raters (overall agreement
92.86%, expected agreement by chance 76.08%, kappa =
0.701, 𝑍 = 3.87, and 𝑝 = 0.001). Full details of the main
diagnostic comparison are appended in Table 3. When the
analysis was weighted for the relative functional impairment
of the three groups the results were very similar: the percent
overall agreement was 88.43% (expected agreement 45.44%)
and the kappa was 0.788 (𝑍 = 16.22, 𝑝 < 0.001, and 95% CI
from 0.693 to 0.883).
3.3. Qualitative Analysis and Equipercentile Linking of
CAARMS 12/2006 and SIPS 5.0. Post hoc analyses (see eTable
3) confirmed an overall substantial agreement across the two
instruments with the exception of the cell [2,5: CAARMS
12/2006-BLIPS versus SIPS 5.0-Psychosis, adjusted residual =
3.7]. This indicates that, out of the 25 subjects diagnosed
with BLIPS by the CAARMS 12/2006, 14 were diagnosed as
psychotic by the SIPS 5.0 (eTable 3). The count in this cell
was statistically higher than the count expected by chance.
To better elucidate these differences we have conducted
a qualitative analysis of psychopathological characteristics
of these 14 patients, which is appended in eTable 4. The
equipercentile linking between severity and frequency scores
of the two instruments is detailed in Table 4.
3.4. Development and Validation of an Automatized Con-
version Algorithm (CONVERT). The pragmatic algorithm to
convert individual cases across the SIPS 5.0 and theCAARMS
12/2006 is depicted in Figure 1.
The steps illustrated in Figure 1 have been fully autom-
atized in the CONVERT tool, which is appended online
(https://bitbucket.org/ioppn/convert) with further informa-
tion for users. The tool was first piloted on the OASIS
and CAMEO sample and it was able to correctly convert
all cases between the two instruments. External validation
was performed in an independent sample assessed for sus-
picion of UHR symptoms at the Seoul Youth Clinic (see
eTable 5). For the SIPS 5.0-to-CAARMS 12/2006 CONVERT
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Table 3: Diagnostic comparison between CAARMS 12/2006 and SIPS 0.5 outcomes in subjects seeking help from high-risk services (𝑝 <
0.001).
SIPS outcome
UHR− UHR+ Psychotic Total
CAARMS outcome
UHR−
Count 51 0 0 51
% 24.1% 0.0% 0.0% 24.1%
Adj Res 13.5 −7.8 −4.8
UHR+
Count 5 92 14 111
% 2.4% 91.1% 6.6% 52.4%
Adj Res −7.7 10.8 −4.5
Psychotic
Count 1 9 40 50
% 0.5% 4.2% 18.9% 23.6%
Adj Res −4.5 −4.8 10.1
Total Count 57 101 54 212
% 29.6% 47.6% 25.5% 100.0%
CAARMS, Comprehensive Assessment of At-Risk Mental States; SIPS, Structured Interview for Psychosis-Risk Syndrome; UHR, ultra high risk; Adj Res,
adjusted residuals; adjusted residuals lower than −3.29 or greater than 3.29 indicate that the number of cases in that cell is significantly larger or small than
expected under the null hypothesis at 𝑝 < 0.001 corrected for multiple comparisons. No cells have expected count less than 5. The minimum expected count
is 12.74.
conversion, the percent overall agreement was of 92.47%
(expected agreement 56.63%), kappa = 0.826 (95% CI from
0.623 to 1), PABAK = 0.85, sensitivity = 83.87%, specificity =
96.77%, and ROC area = 0.903 (95% CI from 0.833 to
0.972). For the CAARMS 12/2006-to-SIPS 5.0 CONVERT
conversion, the percent overall agreement was of 98.92%
(expected agreement 86.99%), kappa = 0.917 (95% CI from
0.714 to 1), PABAK = 0.98, sensitivity = 100%, specificity =
85.7%, and ROC area = 0.929 (95% CI from 0.789 to 1).
4. Discussion
This is the first pilot study addressing comparability of the two
psychometric instruments most frequently used to interview
subjects seeking help from high-risk services for psychosis.
Strengths of this study include enrolment of a relatively
large sample size inclusive of UHR+, UHR−, and psychotic
patients, the use of kappa analyses and equipercentile-linking
methods, the development of automatized algorithms, and
the use of external validation samples of different ethnic
background. We found an overall substantial agreement
between CAARMS 12/2006 and SIPS 5.0 in the identification
of UHR subjects, with the exception of BLIPS.These findings
however may be influenced by the type of recruitment
strategies adopted by the high-risk services. Residual and
qualitative analyses and equipercentile-linking tables pro-
vided additional comparability data. The automated conver-
sion algorithm (CONVERT) to convert individual cases was
validated in an independent sample and showed an excellent
accuracy.
Our first aim was to test the diagnostic comparability of
CAARMS 12/2006 versus SIPS 5.0 in a large sample of more
than 200 subjects referred for psychometric diagnostic inter-
view to high-risk services. We found an overall substantial
agreement (kappa) between the CAARMS 12/2006 and SIPS
5.0. Such a substantial agreement is not completely surpris-
ing. First, the two instruments show similar psychometric
parameters, such as excellent reliability properties (overall
IRR agreement for the SIPS 0.95 [25], for the CAARMS
0.85 [6]). Second, independent authors not involved with
the development of the two instruments argue that the
development of the SIPS was influenced by the CAARMS.
Specifically, they claimed that the SIPS was developed at
the PRIME Clinic “to evaluate the severity of ARMS, as
defined by [9].” Third, in our previous meta-analysis we
found that the CAARMS and the SIPS can identify a similar
proportion of true positives over time (transition risk by 31
months with the CAARMS = 27.4%, 95% CI from 24.6%
to 30.4%; transition risk by 31 months with the SIPS =
28.1%, 95% CI from 25.1% to 31.3%; 𝑝 = 0.73) [12].
Finally, in a recent meta-analysis we specifically confirmed
that, in help-seeking samples, the two instruments share
similar excellent prognostic accuracy in ruling out psychosis
risk, with no significant differences [26]. On the basis of
the above substantial agreement, our findings are the first
to address the “Babylonian confusion” of UHR diagnostic
interview, making it easier to overall compare the results
of UHR research, which had formerly been difficult and
risky [9]. Indeed, the definition of case (i.e., whether or
not a subject has the condition of interest) is highly prob-
lematic across the entirety of clinical psychiatry, where no
objectively assessable measures/markers/tests/exams other
than clinical impression usually exist to establish the pres-
ence or absence of a given condition. Our results are
thus highly relevant to permit overall meaningful com-
parisons of clinical, neurobiological, neurocognitive, and
cost-effectiveness UHR studies worldwide, with poten-
tial beneficial impact for ongoing large-scale multicentre
UHR projects such as the PRONIA (http://www.pronia.eu/),
NAPLS (http://napls.commons.yale.edu/), and PSYSCAN
(http://www.psyscan.eu/).
Our secondary aim was to qualitatively investigate
potential discrepancies across the two instruments and
to provide equipercentile-linking comparisons. The
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Table 4: Equipercentile-linking table comparing symptoms severity and frequency across CAARMS 12/2006 and SIPS 5.0 in the OASIS and
CAMEO sample.
Domain Severity scores Frequency scores
CAARMS to SIPS SIPS to CAARMS CAARMS to SIPS SIPS to CAARMS
P1 CAARMS to P1 SIPS
& P1 SIPS to P1
CAARMS
0 0.012 0 0.011 0 0.019 0 0.017
1 1.092 1 0.916 1 0.718 1 1.690
2 2.212 2 1.816 2 1.163 2 3.321
3 3.258 3 2.759 3 1.781 3 5.282
4 4.180 4 3.799 4 2.481
5 5.019 5 4.976 5 2.899
6 5.965 6 6.033 6 3.289
P2 CAARMS to P2 SIPS
0 0.026 0 0.028
1 1.059 1 0.602
2 2.234 2 1.001
3 3.216 3 1.669
4 4.105 4 2.406
5 5.956 5 2.861
6 5.961 6 3.271
P2 CAARMS to P3 SIPS
0 0.041 0 0.004
1 0.124 1 0.027
2 0.178 2 0.071
3 0.112 3 0.106
4 0.297 4 0.237
5 0.464 5 0.469
6 2.692 6 2.462
P2/P3 SIPS∗ to P2
CAARMS
0 0.007 0 0.062
1 0.919 1 1.779
2 1.778 2 3.541
3 2.735 3 5.478
4 3.806
5 4.991
6 6.025
P3 CAARMS to P4 SIPS
& P4 SIPS to P3
CAARMS
0 0.012 0 0.013 0 0.007 0 0.007
1 0.893 1 1.112 1 0.625 1 1.984
2 1.891 2 2.106 2 1.001 2 3.347
3 2.953 3 3.045 3 1.701 3 4.899
4 3.944 4 4.059 4 2.537
5 4.861 5 5.153 5 3.034
6 5.876 6 6.099 6 3.530
P4 CAARMS to P5 SIPS
& P5 SIPS to P4
CAARMS
0 0.067 0 0.079 0 0.080 0 0.095
1 0.855 1 1.126 1 0.594 1 1.743
2 1.981 2 2.017 2 1.133 2 3.612
3 3.032 3 2.968 3 1.666 3 5.234
4 4.064 4 3.936 4 2.193
5 5.158 5 4.844 5 2.798
6 6.090 6 5.889 6 3.472
P1–P4 on the CAARMS and P1–P5 on SIPS are defined in Table 1; ∗using the highest score across P2 and P3 SIPS. For analytical purposes in this table the SIPS
frequency was coded as follows: 1: ≥1 h/d, ≥4 d/wk; 2: ≥several minutes/d, ≥1x/mo; 3: ≥1x/wk; 0: none of the above.
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Figure 1: Pragmatic algorithms to convert CAARMS 12/2006-versus-SIPS 5.0 individual cases, automatized in the package CONVERT, which
is appended online at https://bitbucket.org/ioppn/convert.
equipercentile-linking table (Table 4) suggests a close
relationship between the symptoms severity and frequency
scores of the CAARMS 12/2006 and SIPS 5.0, as also
confirmed by equipercentile-linking analyses of SOFAS
and GAF measures [27]. However, we also found some
sources of disagreement, in particular, with respect to the
diagnosis of BLIPS subjects. Indeed 14 out of the 25 BLIPS
subjects diagnosed by the CAARMS 12/2006 were diagnosed
as already psychotic by the SIPS 5.0 (eTable 4). There are
significant differential operationalizations of the BLIPS
across the two instruments. On one side the psychosis
threshold is higher in the SIPS 5.0 than in the CAARMS
12/2006 (psychotic symptoms may last more than 7 days);
on the other it is lower since the symptoms should not have
urgency features [28] (“urgency is any positive psychotic
symptom that is seriously disorganizing or dangerous no
matter what the duration” (SIPS 5.0 manual page 15 [8])). To
elucidate this difference we conducted a qualitative analysis
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of the medical records of these 14 subjects. We confirmed
that all of them were presenting with disorganized or
dangerous symptoms (see definition in Table 2), which were
meeting BLIPS criteria under the CAARMS 12/2006 (eTable
3) while at the same time being regarded as over threshold
for psychosis with the SIPS 5.0. Since South London has
one of the highest rates of psychosis in the world [17],
BLIPS subjects alone represent about 9% of OASIS patients,
with an additional 9% meeting conjointly APS or GRD
criteria (Figure 6 from [17]). Conversely, operationalization
differences in BLIPS duration (i.e., less than 7 days on the
CAARMS 12/2006) affected only 4 subjects in our database
(eTable 3). This may be partially due to the fact that our
referrers are trained to refer only BLIPS subjects defined
by the CAARMS 12/2006 criteria. Similarly, differences on
psychosis threshold in the Perceptual Abnormalities subscale
(i.e., severity of 6 on the SIPS 5.0 and 5 on the CAARMS
12/2006) affected only 6 subjects in our database (eTable 3).
Conversely, operationalization differences of the APS,
which includes four domains (P1–P4) in the CAARMS
12/2006 and five in the SIPS 5.0 (P1–P5), did not play a
significant role (eTable 3). It is possible to speculate that the
additional SIPS 5.0 domain, Grandiose Ideas, with manic or
hypomanic features is not particularly frequent or severe in
UHR subjects (4 subjects only had higher scores on SIPS
5.0 P3 as compared to SIPS 5.0 P2). Also, operationalization
differences in APS onset criteria did not impact the overall
consistency of the diagnostic interview for APS across the
two instruments. This is somewhat surprising giving that
CAARMS 12/2006 permits positive symptoms to qualify even
if they are no longer present in the past month, whereas
SIPS 5.0 requires them to be present in the past month.
Also, the functional decline criterion (i.e., SOFAS drop),
which is explicitly used in the CAARMS 12/2006 but not in
the SIPS 5.0, did not impact the diagnostic agreement (see
limitations below).This finding however is also supported by
our recent meta-analysis showing that both SIPS-defined and
CAARMS-defined UHR samples display consistent baseline
functional impairments as compared to matched controls
[20]. Similarly, there was no effect for the assessment of
differential diagnoses associated with comorbidities [29]
between the CAARMS 12/2006 (which does not consider
comorbidities) and SIPS 5.0 (in which the UHR+ diagnosis
should not be made if the symptoms are better explained
by other comorbid disorders; this affected only 5 subjects
in our database; see eTable 3). However, the notion “better
explained” is poorly coded and may therefore be subject to
arbitrary clinical judgment: no studies have ever addressed
the impact of this criterion on subjects identified by the SIPS.
Because of this, comorbid disorders may be highly prevalent
in both the CAARMS 12/2006 and the SIPS 5.0. Indeed in our
meta-analysis specifically investigating comorbid affective
disorders in UHR subjects, we found a similar prevalence of
anxiety or depressive disorders in SIPS [30, 31] and CAARMS
[32] studies.
Our third aim was to develop an automated algorithm
to convert individual cases and to validate it in an external
sample. Therefore, on the basis of the CAARMS 12/2006
and SIPS 5.0 differences in operationalizations detailed in
Tables 1 and 2, we were finally able to develop and propose
a pragmatic algorithm to convert the main clinical outcomes
across the two instruments (see Figure 1). This algorithm has
been implemented in the CONVERT tool, which has been
made freely available for the use of future researchers and
clinicians and externally validated in an independent sample.
We found that CONVERT performed in the excellent range
of accuracy in both directions: the ROC area was 0.903 for
the SIPS 5.0-to-CAARMS 12/2006 conversion and 0.929 for
the CAARMS 12/2006-to-SIPS 5.0 conversion.The ROC area
serves as a global measure of test performance and values in
the range of 0.9–1 are considered excellent, between 0.8 and
0.9 very good, between 0.7 and 0.8 good, between 0.6 and
0.7 sufficient, and between 0.5 and 0.6 bad [33]. Of relevance,
CONVERT was developed on a priori differences between
CAARMS 12/2006 and SIPS 5.0 operationalizations (Tables
1 and 2), and its performance was tested against an external
validation sample that was characterized by a different ethnic
background. Because of this, we expect that CONVERT
could perform well in other UHR samples and we hope that
it will facilitate data merging across UHR sites employing
different diagnostic instruments. This may support large-
scale multicentre UHR analyses across PRONIA, PSYSCAN,
or NAPLS or replication studies to consolidate the current
UHR findings.
This study had limitations. First, we did not perform a
follow-up. Second, the type of recruitment adopted in OASIS
and CAMEO services may have impacted the observed sub-
stantial agreement between CAARMS 12/2006 and SIPS 5.0.
For example, the close link of the OASIS or CAMEOwith the
local first-episode servicesmay have increased the proportion
of disorganizing/dangerous BLIPS or the clinical composition
of subjects referred for UHR assessment to our services
[34]. Also, our referrers underwent a long-standing training
to identify and signpost subjects meeting the functional
deterioration criterion according to the CAARMS 12/2006
intake criteria. Therefore, it is possible that UHR patients
meeting SIPS 5.0 criteria (e.g., with attenuated psychotic
symptoms but without functional deterioration) may have
been undetected by referrers and not assessed at all by
our teams, inflating the observed agreement. Indeed, when
the CAARMS 12/2006 was compared with the SIPS 5.0 in
other epidemiological samples of non-help-seeking subjects,
significant differences between the two instruments were
observed [35] (the use of UHR instruments in non-help-
seeking samples is not recommended however [11]). There is
also recent meta-analytical evidence indicating that samples
referred to high-risk services are highly heterogeneous and
that their actual compositionmay reflect the type of outreach
campaigns adopted [36, 37]. Future studies should investigate
the likely possibility of a lower agreement between CAARMS
12/2006 and SIPS 5.0 in high-risk services employing SIPS-
based outreach campaigns. Third, our procedure involving
a unique rater scoring both instruments in an uncontrolled
ordermay have significantly inflated agreement across instru-
ments. However, assessing subjects referred for suspicion of
UHR symptoms at the time of the first contacts with high-
risk services (who may be already psychotic or eventually
deemed not at risk of psychosis) with independent raters
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poses severe logistic difficulties for the patients. It may also
paradoxically create additional biases because themost severe
patients may be more likely to decline lengthy assessments.
To control for this we performed an independent analysis in
a subset of patients (𝑛 = 21) assessed with independent raters
and we confirmed that magnitude of agreement remained
substantial (see results in eMethod 1). Interrater reliability of
the original instruments has been investigated in even smaller
samples (𝑛 = 14) [25]. Fourth, given the differences in the
two instruments' development itself [10], our findings and
the CONVERT tool may not be applied to older versions
of the instruments. Fifth, psychometric reconciliation of the
CAARMS versus SIPS is not sufficient to mitigate the differ-
ences between the various UHR research teams. Differences
remain between the characteristics of the basic population,
the recruitment of patients, the follow-up, and the specific
treatments provided [9].
5. Conclusions
There is overall substantial diagnostic agreement between
the CAARMS 12/2006 and SIPS 5.0 towards identification of
UHR subjects. Disagreement was mostly due to differential
operationalization of BLIPS. However, type of recruitment
strategies may have inflated the observed agreement and
future studies should repeat these analyses in high-risk ser-
vices adopting different outreach campaigns. The conversion
algorithm, CONVERT, had excellent performance character-
istics even in samples of different ethnic background. The
results of the current investigation may be highly relevant
to the field, as they may inform future multicentre studies
as well as international consensus conferences aiming at
standardizing the UHR diagnostic interview.
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UHR+: At ultra high risk of psychosis
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